Impact des nouveaux antirétroviraux chez les patients infectés par le VIH en échec virologique

Dominique Costagliola

doi:10.1051/medsci/2012288011

Accueil

Tous les numéros

Volume 28 / Numéro 8-9 (Août–Septembre 2012)

Med Sci (Paris), 28 8-9 (2012) 706-707

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 28, Numéro 8-9, Août–Septembre 2012


Page(s)		706 - 707
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/2012288011
Publié en ligne		22 août 2012

Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from EuroSIDA study. Antiviral Therapy 2002 ; 7 : 21–30. [PubMed] [Google Scholar]
Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004 ; 364 : 51–62. [CrossRef] [PubMed] [Google Scholar]
Costagliola D, Potard V, Duvivier C, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antiviral Therapy 2005 ; 10 : 563–573. [PubMed] [Google Scholar]
Lodwick L, Costagliola D, Reiss P, et al. Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years. Arch Intern Med 2010 ; 170 : 410–419. [CrossRef] [PubMed] [Google Scholar]
Nakagawa F, Lodwick R, Costagliola D, et al. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr 2012 ; 59 : 294–299. [PubMed] [Google Scholar]
Costagliola D, Lodwick R, Ledergerber B, et al. Trends over calendar time in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012 ; 12 : 119–127. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from EuroSIDA study. Antiviral Therapy 2002 ; 7 : 21–30. [PubMed] [Google Scholar]

[2] Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004 ; 364 : 51–62. [CrossRef] [PubMed] [Google Scholar]

[3] Costagliola D, Potard V, Duvivier C, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antiviral Therapy 2005 ; 10 : 563–573. [PubMed] [Google Scholar]

[4] Lodwick L, Costagliola D, Reiss P, et al. Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years. Arch Intern Med 2010 ; 170 : 410–419. [CrossRef] [PubMed] [Google Scholar]

[5] Nakagawa F, Lodwick R, Costagliola D, et al. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr 2012 ; 59 : 294–299. [PubMed] [Google Scholar]

[6] Costagliola D, Lodwick R, Ledergerber B, et al. Trends over calendar time in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012 ; 12 : 119–127. [CrossRef] [PubMed] [Google Scholar]